Table 2.
Tolerability and systemic adverse effects experienced by Pfizer vaccine recipients after second dose10.
| |
Individuals 18 to 55 |
|
Individuals 55 and older |
|
|---|---|---|---|---|
| Mild to moderate | Severe (symptoms prevent daily activity) | Mild to moderate | Severe (symptoms prevent daily activity) | |
| Tolerability (Local and immediate reactions) | ||||
| Injection Site Pain | 76.6% | 1.2% | 65.7% | 0.5% |
| Erythema | 5.4% | 0.5% | 6.8% | 0.5% |
| Swelling | 5.9% | 0.3% | 7.3% | 0.2% |
| Systemic Reactions | ||||
| Headache | 48.5% | 3.2% | 38.4% | 0.5% |
| Fatigue | 54.8% | 4.6% | 47.7% | 2.8% |
| Myalgia | 37.3% | 2.2% | 27.8% | 1.0% |
| Vomiting | 1.7% | 0.2% | 0.6% | 0.1% |
| Fever | 30.2% | 1.2% | 21.5% | 0.3% |